Bioequivalence study of BETALOC-XR™ (Drug International Ltd, Bangladesh) and METOPROLOL 100 STADA™ (STADA Pharm Gmbh, Germany) as open-label, two-way crossover and randomized fashion among healthy male volunteers
Bioequivalence study of two oral formulations of metoprolol 100 mg tablet was brought about in 16 healthy male Bangladeshi normal individuals as crossover-randomized fashion. The test and reference formulated products were BETALOC-XR™ (Drug International Ltd, Bangladesh) and METOPROLOL 100 STADA™ (STADA Pharm Gmbh, Germany). Each tablet was delivered with 150 mL of water to every normal individual after whole night fasting on two treatment days separated by more than one week washout period. After administering drug, blood samples were collected serially for a period of 24 hours. A validated HPLC method was used to estimate the plasma concentrations of metoprolol. The pharmacokinetic parameters Cmax, Tmax, AUC0→24h, t1/2, and Kel were determined in this study. The mean (± SD) AUC0→24h for test drug BETALOC-XRTM was 490.3 ± 187.5 ng/hr/mL whereas for reference drug METOPROLOL 100 STADATM it was 559.9 ± 267.2 ng/hr/mL. The relative bioavailability (BETALOC-XRTM/METOPROLOL 100 STADATM ratio) was 87.5%. The Cmax, tmax, half-life of elimination (t1/2) and the rate of elimination (Kel) for test drug was 170.9 ± 78.3 ng/mL, 2.3 ± 0.8 hours, 1.2 ± 2.0 hour and 0.4362 whereas for reference drug was 209.1 ± 91.3 ng/mL, 1.7 ± 0.7 hours, 1.3 ± 2.2 hour and 0.5875 respectively. Based on these statistical hypothesis it was conjecture that a BETALOC-XRTM tablet is bioequivalent to a METOPROLOL 100 STADATM tablet.
2. “Metoprolol” American Society of Health-System Pharmacists. Archived from the original on 12 March 2014. Retrieved 21 April 2014.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Wilkoff BL, American College of Cardiology F, American Heart Association J Am Coll Cardiol. 2013;62:e147-239.
4. O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Circulation. 2013; 127:e362-425.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7.
6. Geffner DL, Hershman JM (July 1992). "Beta-adrenergic blockade for the treatment of hyperthyroidism". Am.J.Med. 93 (1):61–8. doi:10.1016/0002-9343(92)90681 Z. PMID135 2658
7. Ablad B, Borg KO, Carlsson E, Johnsson G, Regardh CG. Metoprolol. Pharmacol Biochem Prop Drug Subst 1979;2:186-228.
8. Brogden RN, Heel RC, Speight TM, Avery GS. Metoprolol - A review of its pharmacological properties and therapeutic efficacy inhypertension and angina pectoris. Drugs 1977;14:321-48.
9. Regardh CG, Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokin 1980;5:557-69.
10. Ablad B, Borg KO, Carlsson E, Ek L, Johnsson G, Malmfors T, Regardh CG. A survey to the pharmacological properties of metoprololin animals and man. Acta Pharmaco Toxicol 1975; 36 Suppl V:7-23.
11. Regardh CG, Jordo L, Ervik M, Lundborg P, Olsson R, Ronn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokin 1981;6:375-88.
12. Swaisland HC, Ranson M, Smith RP, Leadbetter J, Laight A, McKillop D, Wild MJ (2005). "Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol". Clinical Pharmacokinetics. 44 (10): 1067–1081. doi:10.2165/00003088-200544100-00005. PMID 16176119. S2CID 1570605.
13. Blake CM, Kharasch ED, Schwab M, Nagele P (September 2013). "A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics". Clin Pharmacol Ther. 94 (3): 394–9. doi:10.1038/clpt.2013.96. PMC 3818912. PMID 23665868
14. Pillay (2012). Modern Medical Toxicology. Jaypee Brothers Publishers. p. 303. ISBN 9789350259658. Archived from the original on 7 July 2017.
15. Marx, John A. Marx (2014). "Cardiovascular Drugs". Rosen's emergency medicine : concepts and clinical practice (8th ed.). Philadelphia, PA: Elsevier/Saunders. pp. Chapter 152. ISBN 978-1455706051
16. "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014 Archived from the original on 8 April 2014. Retrieved 22 April 2014
17. Medical Toxicology. Lippincott Williams & Wilkins. 2004. p. 684. ISBN 97807817284 -54. Archived from the original on 7 July 2017
18. "Metoprolol vs Toprol-XL Comparison". Drugs.com. 1 August 2019. Retrieved 24 September 2019.
19. "Metoprolol Tartrate vs. Metoprolol Succinate: A Comparison". Healthline. 28 February 2018. Archived from the original on 25 September 2019. Retrieved 24 September 2019.
20. Eske, Jamie (25 September 2019). "Metoprolol tartrate vs. succinate: Differences in uses and effects". Medical News Today. Archived from the original on 25 September 2019. Retrieved 24 September 2019
21. Shah VP, Midha KK, Dighe S, et al. Conference report: Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991; 16: 249–255.
22. Kinetica TM2000. Version 3.0, Innaphase, User Manual, 1999.
23. Uesugi T. FDA. Bioanalytical method validation. Food and drug administration. Guidance for Industry. 2001:1–22;
24. Westlake WJ. Bioavailability, bioequivalence of pharmaceutical formulations. In Biopharmaceutical Statistics for Drug Development, Peace KE (ed.). Marcel Dekker: New York, 1988; 329–352.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).